Malissa Phillips
Family · Bolivar, MONPI 1851404776
Payments from drug & device makers
Across 346 payments — averaging $17.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$615
- AstraZeneca$516
- Abbott$480
- Lilly USA, LLC$435
- Pfizer$395
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,951100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 57 | $1,057 |
| Novo Nordisk | 36 | $615 |
| AstraZeneca | 23 | $516 |
| Abbott | 23 | $480 |
| Lilly USA, LLC | 27 | $435 |
| Pfizer | 26 | $395 |
| Amgen | 26 | $389 |
| GSK | 20 | $292 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $219 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $202 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $157 |
| Biohaven Pharmaceuticals, Inc. | 14 | $146 |
| Otsuka America Pharmaceutical, Inc. | 7 | $132 |
| E.r. Squibb & Sons, L.L.C. | 5 | $95 |
| Exact Sciences | 5 | $91 |
| Dexcom, Inc. | 5 | $87 |
| Braeburn Inc. | 3 | $73 |
| Organon | 6 | $71 |
| Amarin Pharma, Inc. | 3 | $65 |
| Eisai Inc. | 3 | $59 |
| Novartis | 4 | $58 |
| Teva Pharmaceuticals USA, Inc. | 3 | $46 |
| Boehringer Ingelheim | 2 | $39 |
| Alkermes, Inc. | 2 | $35 |
| Merck | 2 | $30 |
| Collegium Pharmaceutical, Inc. | 2 | $26 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Vertex | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$117
- NURTEC ODT$107
How this compares
$5,951 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 56 | $56,387 |
| OzempicSemaglutide | 34 | $50,163 |
| TrulicityDulaglutide | 44 | $46,559 |
| MounjaroTirzepatide | 35 | $35,771 |
| FarxigaDapagliflozin Propanediol | 28 | $35,577 |
| MyrbetriqMirabegron | 51 | $24,374 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $22,082 |
| JardianceEmpagliflozin | 15 | $14,894 |
| JanuviaSitagliptin Phosphate | 12 | $13,157 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $11,985 |
| Incruse ElliptaUmeclidinium Bromide | 24 | $8,223 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $7,912 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $6,435 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $5,126 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 18 | $4,820 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $435 | $82,33079 claims |
| PfizerEliquis, Abrysvo | $395 | $61,20774 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $516 | $53,99672 claims |
| Novo NordiskOzempic | $615 | $50,16334 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta | $292 | $38,21769 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $39 | $20,02026 claims |
| MerckJanuvia | $30 | $13,15712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,812 family providers in Missouri.
Other family in Bolivar
- Bailey ShunyakovBolivar$27K
- Bethany MartinBolivar$17K
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.